Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY6 | Q15077 | 9/20 | 0.46 |
| ▸ | P2RY2 | P41231 | 8/20 | 0.46 |
| ▸ | P2RY4 | P51582 | 7/20 | 0.46 |
| ▸ | P2RY14 | Q15391 | 9/20 | 0.45 |
| ▸ | B4GALT1 | P15291 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cytosine SCHEMBL9768402 | 0.98 | P2RY14 (0.45) | P2RY6P2RY2P2RY4P2RY14B4GALT1 | |
| Cytosine SCHEMBL1687124 | 0.90 | ALDH1A1 (0.44) | P2RY6P2RY2P2RY4P2RY14ALDH1A1 | |
| Cytosine SCHEMBL3954369 | 0.81 | P2RY2 (0.50) | P2RY6P2RY2P2RY4P2RY14 | |
| Cytosine SCHEMBL11403996 | 0.80 | PRKAG1 (0.33) | P2RY6P2RY2P2RY4 | |
| SCHEMBL1888557 | 0.79 | P2RY14 (0.48) | P2RY6P2RY2P2RY4P2RY14B4GALT1 | |
| SCHEMBL442899 | 0.79 | P2RY14 (0.48) | P2RY6P2RY2P2RY4P2RY14B4GALT1 | |
| Cytosine SCHEMBL10496378 | 0.79 | POLG (0.38) | P2RY2 | |
| SCHEMBL1073216 | 0.79 | P2RY14 (0.48) | P2RY6P2RY2P2RY4P2RY14B4GALT1 | |
| Triphosphate SCHEMBL76046 | 0.78 | POLG (0.36) | — | |
| Ribose (Furanose) SCHEMBL8833 | 0.77 | LMNA (0.49) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-60089423-A | — | — | None | — | — | JP | disclosed |
| EP-3429570-B1 | COMBINATIONS OF LSD1 INHIBITORS FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES | ORYZON GENOMICS SA (ES) | 2026-05-20 | — | — | EP | disclosed |
| US-12594293-B2 | Use of 6-thio-dG to treat therapy-resistant telomerasepositive pediatric brain tumors | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-04-07 | — | — | US | disclosed |
| US-20260034116-A1 | CANCER COMBINATION THERAPY INCLUDING A BCL-2 INHIBITOR | RYVU THERAPEUTICS S A (PL) | 2026-02-05 | — | — | US | disclosed |
| EP-4561578-A1 | CANCER COMBINATION THERAPY INCLUDING A BCL-2 INHIBITOR | Ryvu Therapeutics S.A. (PL) | 2025-06-04 | — | — | EP | disclosed |
| CN-119836291-A | Combination therapy for cancer comprising BCL-2 inhibitors | 雷沃医疗有限公司 | 2025-04-15 | — | — | CN | disclosed |
| US-20240424013-A1 | SEQUENTIAL TREATMENT OF CANCERS USING 6-THIO-dG, CHECKPOINT INHIBITORS AND RADIATION THERAPY | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-12-26 | — | — | US | disclosed |
| EP-4117667-B1 | SEQUENTIAL TREATMENT OF CANCERS USING 6-THIO-DG AND CHECKPOINT INHIBITORS | UNIV TEXAS (US) | 2024-12-18 | — | — | EP | disclosed |
| US-12097213-B2 | Sequential treatment of cancers using 6-thio-dG, checkpoint inhibitors and radiation therapy | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-09-24 | — | — | US | disclosed |
| CN-110536703-B | Combination therapy using anti-AXL antibody-drug conjugates | ADC治疗有限公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20130035253-A1 | METHODS FOR DIAGNOSIS, PROGNOSIS AND METHODS OF TREATMENT | NODALITY, INC. A DELAWARE CORPORATION (US) | 2013-02-07 | — | — | US | disclosed |
| WO-2012100017-A2 | ANTIRETROVIRAL CYCLONUCLEOSIDE COMPOSITIONS AND METHODS AND ARTICLES OF MANUFACTURE THEREWITH | LENTX, INC. (US) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012024546-A2 | INCORPORATION OF HEALTH MEASURMENTS IN ANALYSIS AND INTERPRETATION OF FUNCTIONAL BIOLOGICAL RESPONSE DATA | NODALITY, INC. (US) | 2012-02-23 | — | — | WO | disclosed |
| US-20110151020-A1 | ACTIVE SUBSTANCE COMBINATION WITH GEMCITABINE FOR THE TREATMENT OF EPITHELIAL CANCER | HEESCHEN CHRISTOPHER | 2011-06-23 | — | — | US | disclosed |
| EP-2249844-A1 | ACTIVE SUBSTANCE COMBINATION WITH GEMCITABINE FOR THE TREATMENT OF EPITHELIAL CANCER | Ludwig-Maximilians-Universität München (DE) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009112266-A1 | ACTIVE SUBSTANCE COMBINATION WITH GEMCITABINE FOR THE TREATMENT OF EPITHELIAL CANCER | LUDWIG-MAXIMILIANS-UNIVERSITÄT (DE) | 2009-09-17 | — | — | WO | disclosed |
| CN-100488977-C | Technology of producing cytidine by chemical synthesizing process | HENAN NORMAL UNIVERSITY XINXIA (CN) | 2009-05-20 | — | — | CN | disclosed |
| CN-100999540-A | Tech, of producing cytidine by chemical synthesizing process | UNIV HENAN NORMAL (CN) | 2007-07-18 | — | — | CN | disclosed |
| JP-S6089423-A | CARCINOSTATIC AGENT | SATO HARUO | 1985-05-20 | — | — | JP | disclosed |
| JP-S0689423-A | — | — | 0001-01-01 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110151020-A1 | ACTIVE SUBSTANCE COMBINATION WITH GEMCITABINE FOR THE TREATMENT OF EPITHELIAL CANCER | SHH, GLI1, HGF | P2RY6 2245/4885P2RY2 2982/4885P2RY4 2433/4885 |
| US-12097213-B2 | Sequential treatment of cancers using 6-thio-dG, checkpoint inhibitors and radiation therapy | MPG, UNG, TERT | P2RY6 840/4885P2RY2 3426/4885P2RY4 2827/4885 |
| US-20240424013-A1 | SEQUENTIAL TREATMENT OF CANCERS USING 6-THIO-dG, CHECKPOINT INHIBITORS AND RADIATION THERAPY | UNG, DCTD, MPG | P2RY6 1040/4885P2RY2 3519/4885P2RY4 2844/4885 |
| US-12594293-B2 | Use of 6-thio-dG to treat therapy-resistant telomerasepositive pediatric brain tumors | POT1, TERF2, TERT | P2RY6 1716/4885P2RY2 2744/4885P2RY4 3454/4885 |
| US-20260034116-A1 | CANCER COMBINATION THERAPY INCLUDING A BCL-2 INHIBITOR | BBC3, BCL3, MCL1 | P2RY6 4263/4885P2RY2 3592/4885P2RY4 4322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.